Effect observation of rabeprazole combined with mosapride in treatment of patients with functional dyspepsia

Objective To explore the clinical effect of rabeprazole combined with mosapride in the treatment of functional dyspepsia(FD). Methods A total of 152 FD patients were divided into control group and combination group according to simple random number table method, with 76 cases in each group. The control group was treated with the gastrointestinal motile drug mosapride, and the combined group was treated with rabeprazole combined with mosapride regimen for 6 weeks. The changes of gastrointestinal drainage rate and adverse reaction rate before and after treatment were compared between the two groups. After treatment, outpatient and telephone follow-up were conducted for 6 months, and the recurrence of FD was observed in the two groups. Results After 6 weeks of treatment, the rates of gastric and intestinal drainage in both groups were significantly higher than those before treatment, and the combined group was significantly higher than those in the control group(P<0.05). The total clinical response rate of the combined group was 90.79%, which was significantly higher than 77.63% in the control group(P<0.05). There was no significant difference in FD recurrence rate between the two groups after 3-month follow-up(P>0.05). The recurrence rate of FD after 6-month follow-up in the combined group was 7.25%, which was significantly lower than 20.34% in the control group(P<0.05). Conclusion Rabeprazole combined with mosapride can significantly improve the gastrointestinal emptying rate and reduce the recurrence rate of FD, and the combination of drugs does not significantly increase adverse reactions.